Results of the joint Pasteur-TheraVectys laboratory’s work on their Covid-19 vaccine candidate based on a lentiviral vector, has been published on October 15. in EMBO Molecular Medicine : EMBO Molecular Medicine

A major advance for a Covid-19 vaccine candidate :

– that protects against genetically distant SARS-CoV-2 variants, as well as the original virus,
– that protects the central nervous system; a point never addressed by first generation vaccines,
– which is suitable for use as a nasal booster, critical in protecting the brain.

All demonstrated in a new pre-clinical model generated in collaboration with the Pasteur transgenic center.

Read the full article on